PRLD Stock Analysis: Buy, Sell, or Hold?
PRLD - Prelude Therapeutics Incorporated
$3.66
0.16 (4.57%)
▲
5d:
-12.02%
30d:
-22.78%
90d:
+30.25%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When PRLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PRLD is down 12.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PRLD is down 12.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PRLD is currently trading at $3.66, which is considered oversold relative to its 30-day fair value range of $4.00 to $4.83. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.9) compared to its historical average (34.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRLD is in a strong uptrend. Immediate support is located at $3.40, while resistance sits at $4.54. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+118.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRLD is in a strong uptrend. Immediate support is located at $3.40, while resistance sits at $4.54. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.00 (+118.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.00 -
$4.83
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.6%)
- BULLISH: Trading 118.6% below Wall St target ($8.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -12.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.00 -
$4.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.40
Resistance Level
$4.54
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.89
Wall Street Target
$8.00
(+118.6%)
Revenue Growth (YoY)
41.0%
PE vs Historical
-3.9 vs 34.9
CHEAP
Share & Embed Analysis
Last updated: June 03, 2026 10:57 PM ET
Data refreshes hourly during market hours. Next update: 11:57 PM
Data refreshes hourly during market hours. Next update: 11:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRLD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David P Bonita
BUY
2815315 shares
2026-04-21
Orbimed Advisors Llc
BUY
2815315 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |
